Dimolegin

DRUG4 trials

Sponsors

PharmaDiall Ltd., Avexima Diol LLC

Conditions

Arthroplasty, Replacement, HipArthroplasty, Replacement, KneeCOVID-19Healthy VolunteersPreventionVenous ThromboembolismVenous Thromboembolism (VTE)

Phase 1

A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217)

CompletedNCT05181241

PharmaDiall Ltd.Healthy Volunteers

Start: 2017-01-25End: 2018-04-25Updated: 2022-01-06

Phase 3

Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

CompletedNCT05185804

PharmaDiall Ltd.COVID-19, Venous Thromboembolism

Start: 2021-02-08End: 2021-10-29Updated: 2022-01-11

Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

CompletedNCT07124819

Avexima Diol LLCArthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Prevention +1

Start: 2024-07-22End: 2025-01-14Updated: 2026-01-16

Unknown Phase

Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study

CompletedNCT07134738

Avexima Diol LLCCOVID-19

Start: 2024-06-07End: 2025-01-15Updated: 2026-01-16

Related Papers

Efficacy and Safety of a New Selective Oral Factor Xa Inhibitor Amidine Hydrochloride for Prevention of Thromboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study

Journal of Venous Disorders2024-06-171 citations